Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

16.7%

3 terminated out of 18 trials

Success Rate

78.6%

-7.9% vs benchmark

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

64%

7 of 11 completed with results

Key Signals

7 with results79% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (3)
P 1 (3)
P 2 (6)
P 3 (2)

Trial Status

Completed11
Terminated3
Active Not Recruiting2
Unknown1
Withdrawn1

Trial Success Rate

78.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT04622670Not ApplicableActive Not Recruiting

Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer

NCT01048853Not ApplicableTerminated

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

NCT04574635Active Not Recruiting

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT02140021Not ApplicableTerminated

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

NCT01101451Phase 3Completed

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

NCT01992861Terminated

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

NCT02921269Phase 2Completed

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

NCT01414608Phase 3Completed

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

NCT03834571Phase 2Withdrawn

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

NCT01266460Phase 2Completed

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01711515Phase 1Completed

Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer

NCT01281852Phase 1Completed

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

NCT01267253Phase 2Completed

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01295502Phase 1Unknown

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

NCT00369122Phase 2Completed

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

NCT00041093Phase 2CompletedPrimary

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT00460356Completed

Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes

NCT00897442Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Showing all 18 trials

Research Network

Activity Timeline